The global immunocytokines market is projected to expand at a promising rate from 2021 to 2031 (forecast period). The unexpected spike in investments for clinical trials to create new molecular structures for cancer treatments has provided the global immunocytokines market with a huge boost. As a result, improved molecular structures with higher tolerance and safety have been introduced. Players active in the global immunocytokines market are now focusing on clinical testing for segments such as tumor necrosis factor, first-generation Interleukin-2, second-generation Interleukin-2, Interleukin-10, Interleukin-12, Interleukin-15, and Interferon.
Moreover, the increased cancer incidence is a major factor projected to propel the global immunocytokines market. The worldwide market is also expected to be propelled by rising healthcare expenditures, increased access to medical treatment, and changing lifestyles, which frequently result in chronic ailments and diseases. Furthermore, the growing pool of geriatrics is anticipated to boost the global immunocytokines market in the upcoming years.
Key players active in the worldwide immunocytokines market are Alkermes Plc, CytImmune, AstraZeneca Plc, Altor Biosciences Corporation, ImmunGene, Apeiron Biologics AG, Cytune Pharma, Inc., MolMed S.p.A., Immunomedics, Inc., Merck KGaA, Paladin Labs, Pfizer, Inc., Nektar Therapeutics, F. Hoffmann-La Roche, Ltd., Valor Biotherapeutics, Teva Pharmaceutical Industries Ltd., and Targa Therapeutics Corporation.
Key market players are involved in clinical trial agreements, mergers and acquisitions, research agreements, licensing agreements, research and development agreements, and others. Moreover, these players are making significant R&D investments in developing immunocytokines.
Cancer is among the major causes of mortality worldwide, with a projected 0.6 million deaths in the United States alone in 2020. The World Health Organization expects the number of new cases of cancer will climb by 70% globally during the next 20 years. Conventional therapeutic approaches, such as radiation therapy, chemotherapy, and surgery, are widely known to have minimal success in late-stage malignancies. Moreover, the highly toxic and non-specific character of standard radiation therapy and chemotherapy has been shown to have a negative impact on patients' life quality.
Immunotherapy has emerged as a versatile alternative within the developing class of targeted anti-cancer treatments, demonstrating the ability to target and eradicate tumor cells specifically. Traditionally, several clinical studies have studied cytokines as a therapeutic technique, primarily as anti-cancer agents. However, systemic administration of such powerful, physiologically active compounds has been linked to a variety of dosage-dependent adverse effects and unfavorable pharmacokinetic characteristics, which, in some ways, impedes dose progression to therapeutically effective levels.
To circumvent the treatment-restricting toxicities of cytokines, researchers are increasingly concentrating on immunocytokines. Immunocytokines are fusion proteins that combine the target selectivity of antibodies with certain cytokines' immunological response-mediating properties. So far, these designed pharmacologically active compounds have shown superior efficacy and lower toxicity when compared to traditional cytokine-based therapy. This is a major factor expected to boost the global immunocytokines market during the forecast period.
Moreover, the growing number of cancer cases and demand for immunotherapy medications to treat tumors and cancers are projected to drive the worldwide immunocytokines market. Furthermore, the advent of novel technologies and rising healthcare expenditure are expected to propel the worldwide immunocytokines market.
The immunocytokines market in North America is expected to grow due to the increased awareness of cancer and its treatments across the region. Moreover, strong investments in clinical trials to find novel therapies and pharmaceuticals for cancer treatment are likely to help the regional market growth.
The Asia Pacific immunocytokines market is projected to expand during the forecast period. Emerging nations such as India, China, Malaysia, and Japan are likely to contribute to the Asia Pacific immunocytokines market in the upcoming years. Moreover, the rapid growth of medical tourism, increased grants and funds from governments to build healthcare infrastructure, and the existence of numerous pharmaceutical companies in the region are projected to boost the regional market growth.
N/A
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Immunocytokines Market
